MENLO PARK, Calif.--(BUSINESS WIRE)--Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, announced today that it plans to conduct an observational, real-world study with Biogen (Nasdaq: BIIB) as the sponsor. The study will utilize the Octave® Precision Care Solution (Octave® Solution) to evaluate 150 patients with MS at the Rocky Mountain MS Clinic, Oklahoma Medical Research Foundation’s (OMRF) MS Center of Excellence, and Orlando Health MS Comprehensive Care Center. Octave’s Solution provides neurologists and their patients with quantitative, objective metrics to facilitate informed care and shared decision making to provide a more personalized MS care approach.
“We believe this study will illustrate the power of the full Octave Solution - insights from biological, radiographic, and clinical phenotype tools - to create a dynamic, longitudinal perspective of a patient with MS,” said William Hagstrom, Octave’s Founder and Chief Executive Officer. “The initiation of this study marks an important milestone as we work with one of the leading companies in MS and neuroscience to obtain deeper insights about patients and their treatments, and ultimately enable improved care for these patients.”
Octave’s Solution provides the industry’s first set of measurement tools that accurately and objectively measure disease activity, progression, and severity, allowing for better management of complex and high-cost neurodegenerative diseases, such as MS. It includes the first and only multivariate blood test to measure MS Disease Activity (MSDA), enhanced MRI analytics and protocols, and a digital clinical program that actively and passively tracks patients day-to-day and connects them with real-time access to expert MS nurse practitioners.
“We are pleased to bring together two pioneering organizations to evaluate multi-modal care for people living with MS,” said Lee Gervitz, PhD, Vice President and Head of North America Medical Affairs at Biogen. “Our team at Biogen looks forward to working with Octave and the participating clinics to pursue our shared goal of improving patient outcomes.”
The first patients in this study are expected to be enrolled by Fall 2023. The study is expected to be conducted for 12 months following patient enrollment.
The objectives of the study:
- To compare disease activity in blood samples of patients with relapsing MS treated with different disease modifying therapies via the MSDA score
- To characterize divergent radiographic trajectories obtained via MRIs processed using Octave’s enhanced imaging analysis
- To evaluate patients’ self-reported symptoms like depression, anxiety, mobility, and emotional state using Octave’s clinical insights program
- To compare ongoing health metrics of patients obtained via wearable technology
- To compare the number of notifiable events among participants on different MS treatments documented by an Octave Nurse Care Partner over the course of the study
“We have been working with the Octave Solution for some time, and the impact it has had on our practice has been significant,” said John F. Foley, MD, Founder of Rocky Mountain MS Clinic. “The data supporting the MSDA test alone is revolutionary, and the full solution will further enable unprecedented insight into our patients.”
“As MS specialists, we strive to provide the best care while advancing the understanding of this devastating disease,” said Gabriel Pardo, MD, Director of the OMRF MS Center of Excellence. “Octave’s Solution offers a robust comprehensive assessment of an MS patient’s evolution in a way we have not had available before, and we are thrilled to be contributing to this important scientific research.”
“Octave is creating a new paradigm of precision care for neurodegenerative disease,” said Amy Gutierrez, MD, FAAN, neurologist at the Orlando Health MS Comprehensive Care Center. “For those of us who have been researching and treating MS for decades, it is a promising step forward for us and, most importantly, for our patients.”
About Octave® Bioscience, Inc.
Octave Bioscience is a commercial stage precision-medicine company delivering a new paradigm of care for multiple sclerosis and other neurodegenerative diseases. Octave’s Precision Care Solution is the industry’s first set of measurement tools that accurately and objectively measure disease activity, progression, and severity, allowing for better management of complex and high-cost neurodegenerative diseases, starting with Multiple Sclerosis (MS). The Octave Solution includes the first and only multivariate blood test to measure MS Disease Activity, enhanced MRI analytics and protocols, and a clinical care program that tracks and connects patients with MS nurse practitioners in real time. By combining and analyzing multiple biological and contextual layers of data, delivering longitudinal and holistic perspectives of each patient, and revealing insights at population levels, the Octave Solution addresses unmet needs across the entire ecosystem of care, from patients and providers to pharma and payers. Octave Bioscience, Inc. is currently collaborating with leading clinics, payers, and pharma companies across the country.
